3 results
Objectives Primary end point:- to define the MTD of IL-2, subcutaneously given once a day, 5 days per week, for 6 weeks, in combination with a fixed dose of sorafenib in patients with metastatic RCC, clear cell subtype. Secondary end points:- the…
Primary ObjectiveThe primary objective of the study is:• To compare the efficacy of 6.0, 7.5, and 9.0 g of FT218 to placebo in treating EDS in both NT1 and NT2 subjects as measured by mean sleep latency on the Maintenance of Wakefulness Test (MWT)…
The purpose of the study is to investigate how quickly and to what extent balovaptan is absorbed and eliminated from the body when it is administered to healthy volunteers. The pharmacokinetics of balovaptan given by mouth (oral) will be compared…